Raffaele Colombo
Zymeworks
Raffaele Colombo is listed as Zymeworks. Raffaele is scheduled to speak at EORTC-NCI-AACR Symposium 2026 (ENA 2026) on 19 November 2026.
Compiled from published conference agendas; not yet confirmed by Raffaele. Is this you? Claim this profile.
About
Raffaele Colombo is an Associate Director, Medicinal Chemistry at Zymeworks [a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics]. He has 15 years of experience in drug conjugates and he is passionate about the intricacies and nuances of ADCs. He earned his Ph.D. in Organic and Medicinal Chemistry from the University of Milan (Italy), working on mall molecule drug conjugates. He then moved to the University of Pittsburgh as part of the NCI's Chemical Biology Consortium (CBC), a discovery engine for the NCI Experimental Therapeutics (NExT) program. In 2014 he was awarded one of the prestigious "Lilly Innovation Fellowship Award (LIFA)" and joined Eli Lilly in Indianapolis, where he developed novel ADC payloads and linkers. He then moved to MedImmune/AstraZeneca, focusing solely on ADC research. In 2020 he joined Zymeworks to lead the medicinal chemistry team to develop novel technologies for AD